Guggenheim Capital’s Dynavax Technologies DVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-23,898
Closed -$368K 1651
2025
Q4
$368K Sell
23,898
-24,366
-50% -$268K ﹤0.01% 1435
2025
Q3
$479K Buy
48,264
+794
+2% +$8.26K ﹤0.01% 1200
2025
Q2
$471K Buy
47,470
+4,005
+9% +$42.2K ﹤0.01% 1218
2025
Q1
$564K Sell
43,465
-3,604
-8% -$47.7K 0.01% 1147
2024
Q4
$601K Sell
47,069
-23,029
-33% -$279K ﹤0.01% 1181
2024
Q3
$781K Buy
70,098
+4,246
+6% +$46.8K 0.01% 1213
2024
Q2
$740K Sell
65,852
-51,263
-44% -$597K 0.01% 1258
2024
Q1
$1.45M Buy
117,115
+782
+0.7% +$10.2K 0.01% 1025
2023
Q4
$1.63M Buy
116,333
+57,605
+98% +$800K 0.01% 933
2023
Q3
$867K Buy
58,728
+6,833
+13% +$96.1K 0.01% 1165
2023
Q2
$670K Buy
51,895
+36,264
+232% +$413K 0.01% 1333
2023
Q1
$153K Sell
15,631
-10,921
-41% -$117K ﹤0.01% 1840
2022
Q4
$283K Buy
26,552
+752
+3% +$8.74K ﹤0.01% 1690
2022
Q3
$269K Sell
25,800
-29,189
-53% -$380K ﹤0.01% 1696
2022
Q2
$692K Buy
+54,989
New +$584K 0.01% 1409
2018
Q4
Sell
-138,719
Closed -$1.72M 2216
2018
Q3
$1.72M Buy
138,719
+19,383
+16% +$262K 0.01% 1325
2018
Q2
$1.82M Buy
119,336
+7,058
+6% +$122K 0.01% 1307
2018
Q1
$2.23M Buy
112,278
+7,522
+7% +$130K 0.01% 1556
2017
Q4
$1.96M Sell
104,756
-4,283
-4% -$86K ﹤0.01% 1687
2017
Q3
$2.35M Buy
+109,039
New +$1.73M 0.01% 1549
2014
Q4
Sell
-1,933
Closed -$28K 3031
2014
Q3
$28K Sell
1,933
-161
-8% -$2.32K ﹤0.01% 2955
2014
Q2
$34K Sell
2,094
-117
-5% -$1.76K ﹤0.01% 3119
2014
Q1
$40K Sell
2,211
-78
-3% -$1.45K ﹤0.01% 3162
2013
Q4
$45K Buy
2,289
+37
+2% +$542 ﹤0.01% 3066
2013
Q3
$27K Buy
2,252
+622
+38% +$7.83K ﹤0.01% 2997
2013
Q2
$18K Buy
+1,630
New +$34.3K ﹤0.01% 2992

Other funds holding DVAX

Guggenheim Capital's DVAX Position: Q1 2026 in Review

Guggenheim Capital sold out of Dynavax Technologies (DVAX) in Q1 2026, closing a stake of 23,898 shares — an estimated $368K sold.

Guggenheim Capital first reported a position in DVAX in Q2 2013 and held it in 26 quarters. The position peaked at $2.35M in Q3 2017. 1 fund tracked by Wall St. Rank holds DVAX as of Q1 2026.

  • Guggenheim Capital reported no remaining Dynavax Technologies position as of Q1 2026 after selling out during the quarter.
  • Guggenheim Capital sold 23,898 Dynavax Technologies shares in Q1 2026, an estimated $368K.
  • Guggenheim Capital first reported a position in Dynavax Technologies in Q2 2013 and held it in 26 quarters.
  • Guggenheim Capital's Dynavax Technologies position peaked at $2.35M in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Dynavax Technologies as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.